UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000010977 |
|---|---|
| Receipt number | R000012852 |
| Scientific Title | A study on the safety and efficacy of hypofractionated radiotherapy in post-operative irradiation for breast cancer patients |
| Date of disclosure of the study information | 2013/06/17 |
| Last modified on | 2025/01/25 15:19:48 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A study on the safety and efficacy of hypofractionated radiotherapy in post-operative irradiation for breast cancer patients
Acronym
A study of hypofractionated radiotherapy for breast cancer
Scientific Title
A study on the safety and efficacy of hypofractionated radiotherapy in post-operative irradiation for breast cancer patients
Scientific Title:Acronym
A study of hypofractionated radiotherapy for breast cancer
Region
| Japan | Asia(except Japan) |
Condition
Condition
Breast cancer
Classification by specialty
| Breast surgery | Radiology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To prove that hypofractionated whole breast irradiation in breast conserving thrapy and hypofractionated post mastectomy regional radiothetapy are as safe and as effective as conventionally fractionated radiotherapy and superior in terms of convenience.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Explanatory
Developmental phase
Phase II
Assessment
Primary outcomes
Local recurrence-free survival rate (in radiation fields)
Key secondary outcomes
Acute adverse events (the skin, subcutaneous tissue, breast tissue, and lungs)
Late advese events (the skin, subcutaneous tissue, breast tissue, lungs, ribs and the heart)
Cosmetic outcome
Base
Study type
Interventional
Study design
Basic design
Factorial
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Dose comparison
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
3
Purpose of intervention
Treatment
Type of intervention
| Maneuver |
Interventions/Control_1
For cases of post breast conserving surgery without high grade factors (age < 50, positive axillary nodes, lymphovascular invasion, or close margins)- 43.2 Gy to the whole breast in 16 fractions over 22 days for (tumor bed boosts are not performed)
Interventions/Control_2
For cases of post breast conserving surgery with positive high grade factors - 43.2 Gy to the whole breast in 16 fractions over 22 days with an additional tumor bed boost of 8.1 Gy in 3 fractions
Interventions/Control_3
For cases of post mastectomy with negative surgical margins - 43.2 Gy to the chest wall and supraclavicular region in 16 fractions over 22 days.
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Female
Key inclusion criteria
1. Eligibility criteria for HF-WBI
Patient who has undergone BCT and have been histopathologically confirmed to have breast cancer
The size of primary tumor is either Tis, T1 or T2
Patient who has undergone a lymph node dissection (including sentinel lymph node biopsy) and has been histopathologically confirmed to have 3 positive lymph nodes or less.
Consent of the patient for the trial obtained
2. Eligibility criteria for HF-PMRT
Patient who has undergone any type of mastectomy and have been histopathologically confirmed to have breast cancer
Patient without positive margin.
Patient who has undergone a lymph node dissection (including sentinel lymph node biopsy) and has been histopathologically confirmed to have less than 8 positive lymph nodes.
Consent of the patient for the trial obtained
Key exclusion criteria
Internal mammary lymph node metastasis.
Residual axillary lymph node or who need to irradiate axially region.
Distant metastasis.
Any active collagen disease
Active double primary cancer (except for carcinoma in situ and bilateral breast cancer)
Concurrent chemoradiotherapy
Previous chest irradiation
Pregnancy and potential pregnancy
Target sample size
400
Research contact person
Name of lead principal investigator
| 1st name | Kumiko |
| Middle name | |
| Last name | Karasawa |
Organization
National Institutes for Quantum and Radiological Science and Technology
Division name
QST Hospital
Zip code
263-8555
Address
4-9-1 Anagawa, Inage-ku, Chiba-city,Chiba, Japan
TEL
043-206-3306
kkarasaw@gmail.com
Public contact
Name of contact person
| 1st name | Kumiko |
| Middle name | |
| Last name | Karasawa |
Organization
National Institutes for Quantum and Radiological Science and Technology
Division name
QST Hospital
Zip code
263-8555
Address
4-9-1 Anagawa, Inage-ku, Chiba-city,Chiba, Japan
TEL
043-206-3306
Homepage URL
kkarasaw@gmail.com
Sponsor or person
Institute
National Institutes for Quantum and Radiological Science and Technology
Institute
Department
Personal name
Funding Source
Organization
National Institutes for Quantum and Radiological Science and Technology
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
National Institutes for Quantum Science and Technology Clinical Research Review Committee
Address
4-9-1 Anagawa, Inage-ku, Chiba-city,Chiba, Japan
Tel
043-206-3306
noriyukiokonogi@gmail.com
Secondary IDs
Secondary IDs
YES
Study ID_1
13-001
Org. issuing International ID_1
National Institute of Radiological Sciences
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
デルタ病院（バングラデシュ）
蘇州大学附属第一医院（中国）
複旦大学上海がんセンター（中国）
インドネシア大学チプト マングンクスモ病院（インドネシア）
ソエトモ総合病院診療センター（インドネシア）
放射線医学総合研究所重粒子医科学センター病院（千葉県）
埼玉医科大学国際医療センター（埼玉県）
弘前大学附属病院（青森県）
群馬大学附属病院（群馬県）
セメイ国立医科大学（カザフスタン）
韓国放射線医科学研究所（韓国）
韓国がんセンター病院（韓国）
サラワク総合病院（マレーシア）
モンゴル国立がんセンター（モンゴル）
聖ルーク医療センター（フィリピン）
フィリピン ホセ・レイエス記念医療センター（フィリピン）
マヒドール大学シリラート病院（タイ）
ホーチミン市腫瘍病院（ベトナム）
国立がんセンター(ベトナム)
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 06 | Month | 17 | Day |
Related information
URL releasing protocol
Publication of results
Partially published
Result
URL related to results and publications
Number of participants that the trial has enrolled
449
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2013 | Year | 05 | Month | 17 | Day |
Date of IRB
| 2013 | Year | 01 | Month | 13 | Day |
Anticipated trial start date
| 2013 | Year | 05 | Month | 17 | Day |
Last follow-up date
| 2029 | Year | 11 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2013 | Year | 06 | Month | 17 | Day |
Last modified on
| 2025 | Year | 01 | Month | 25 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012852
